NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) gapped up prior to trading on Tuesday . The stock had previously closed at $0.51, but opened at $0.62. NovaBay Pharmaceuticals shares last traded at $0.62, with a volume of 14,184 shares.
NBY has been the subject of several analyst reports. LADENBURG THALM/SH SH started coverage on shares of NovaBay Pharmaceuticals in a report on Wednesday, September 18th. They issued a “buy” rating and a $1.10 target price for the company. Zacks Investment Research upgraded shares of NovaBay Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 price objective on the stock in a research report on Wednesday, November 20th.
The company has a 50 day simple moving average of $0.68 and a 200-day simple moving average of $1.02.
About NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)
NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses.
Further Reading: Find a Trading Strategy That Works
Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.